Identification of T cell epitope peptides derived from glioma antigens
| Project/Area Number |
16500225
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Nerve anatomy/Neuropathology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
OHTA Shigeki Keio University, School of Medicine, Instructor, 医学部, 助手 (20365406)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TODA Masahiro Keio University, School of Medicine, Instructor, 医学部, 助手 (20217508)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2005: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2004: ¥2,700,000 (Direct Cost: ¥2,700,000)
|
|---|
| Keywords | glioma / antigen / CTL / immunotherapy / HSV / G207 / GL261 / GARC-1 |
|---|
| Research Abstract |
Despite several ongoing clinical trials of immunotherapies against glioma, few glioma-specific antigens recognized by cytotoxic T lymphocytes (CTLs) have been identified. We recently demonstrated that intratumoral inoculation with herpes simplex virus (HSV) as a cancer vaccine activates tumor-specific CTLs. To identify glioma antigens recognized by CTLs, we used the HSV cancer vaccine to vaccinate mice harboring a syngeneic mouse glioma cell line, GL261. From the splenocytes of the immunized mice, we generated an H-2D^b-restricted CTL line, GCL-1, that was specific for GL261. Then, a cDNA expression library generated from GL261 was screened with GCL-1, and a new gene encoding glioma antigen, GARC-1, was isolated. Sequence analysis revealed that the GARC-1 gene isolated from GL261 had a point mutation causing an amino acid change (Asp to Asn at position 81). T-cell epitope analysis revealed that the mutated peptide GARC-1_<77-85> (AALLNKLYA), but not the wild-type peptide (AALLDKLYA), was recognized by GCL-1. These results suggest that HSV cancer vaccination may be a useful method for inducing tumor-specific CTLs and identifying tumor antigens. Furthermore, this GL261/GARC-1 murine glioma model may be useful for the development of immunotherapy for brain tumors.
|
Report
(3 results)
Research Products
(57 results)
-
-
-
-
-
-
-
-
-
-
[Journal Article] Identification of glioma-specific RFX4-E and -F isoforms and humoral immune response in patients.2005
Author(s)
Matsushita H, Uenaka A, Ono T, Hasegawa K, Sato S, Koizumi F, Nakagawa K, Toda M, Shingo T, Ichikawa T, Noguchi Y, Tamiya T, Furuta T, Kawase T, Date I, Nakayama E
-
Journal Title
Cancer Sci 96(11)
Pages: 801-809
NAID
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] グリオーマ-病態と治療-2006
Author(s)
戸田正博
Total Pages
274
Publisher
シュプリンガー・フェアラーク東京株式会社
Description
「研究成果報告書概要(和文)」より
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
[Patent(Industrial Property Rights)] 癌ワクチン2005
Inventor(s)
戸田正博, 植田良, 塚田晃三
Industrial Property Rights Holder
学校法人慶應義塾大学, 株式会社GBS研究所
Industrial Property Number
2005-012092
Filing Date
2005-01-19
Description
「研究成果報告書概要(和文)」より
Related Report
-
-
-
-
-
-
-
